← Eichor
Study identifier: NCT03222895 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Distribution of Lymph Node Metastases in Esophageal Carcinoma

Condition: Esophageal Neoplasms · Lymph Node Metastases  ·  Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

PhaseN/A
Planned participants5000
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Background: Lymph node status is an important prognostic parameter in esophageal carcinoma and an independent predictor of survival. Distribution of metastatic lymph nodes may vary with tumor location, tumor histology, tumor invasion depth and neoadjuvant therapy. Surgical strategy depends on the distribution pattern of nodal metastases but consensus on the extent of lymphadenectomy differs worldwide. Especially for adenocarcinoma the distribution of lymph node metastases has not yet been described in large series. Aim of the present study is to evaluate the distribution of lymph node metastases in esophageal carcinoma specimens following transthoracic esophagectomy with at least a 2-field lymphadenectomy. Methods: The TIGER-study is a multinational observational cohort study. All patients with a resectable esophageal or gastro-esophageal junction carcinoma in whom a transthoracic esophagectomy with a 2- or 3-field lymphadenectomy is performed in participating centers will be included. All lymph node stations will be excised and separately sent for pathological examination. Cluster analysis will be performed to identify patterns of metastases in relation to tumor location, tumor histology, tumor invasion depth and neoadjuvant therapy. Conclusion: TIGER will provide a roadmap of the location of lymph node metastases in relation to tumor histology, tumor location, invasion depth, number of lymph nodes and lymph node metastases, pre-operative diagnostics, neo-adjuvant therapy …

This description comes directly from the study's public registry record.

Talk to the study team

Suzanne S Gisbertz, MD, PhD  ·  +31205669111  ·  s.s.gisbertz@amc.nl

Eliza RC Hagens, BSc  ·  +31205669111  ·  e.r.hagens@amc.uva.nl

Always discuss trial participation with your own doctor first.

Locations (19)

MD Anderson Cancer CenterHouston, Texas, United StatesRecruiting
Instituto Nacional de CâncerRio de Janeiro, BrazilRecruiting
University of TorontoToronto, CanadaRecruiting
Fudan University Shanghai Cancer CenterShanghai, Yangpu, ChinaRecruiting
Hospital District of Helsinki and UusimaaHelsinki, FinlandRecruiting
University Medical Center of the Johannes Gutenberg UniversityMainz, GermanyRecruiting
University of Athens, School of MedicineAthens, GreeceRecruiting
University of Hong KongHong Kong, Hong KongRecruiting
Tata Memorial CentreMumbai, IndiaRecruiting
IRCCS Policlinico San DonatoMilan, ItalyRecruiting
Ospedale San RaffaeleMilan, ItalyRecruiting
University of VeronaVerona, ItalyRecruiting

+ 7 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03222895